Skip to main content

Table 2 Study population and therapy

From: Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis

Trial Arms N Population Age and PS 0-1 Stage LDH IPI RT
SWOG 8736 CHOP x 8 201 WF groups D-J (DLBCL 75%); stage I to II non-bulky > 60y = 49% 0-1 = 96% II 33% ↑ 19% 0-1 = 71% No RT
  CHOP x 3 + RT 200 >60y = 50% 0-1 = 97% II 32% ↑ 20% 0-1 = 74% IFRT 40-55 Gy
ECOG 1484 CHOP x 8 112 WF H-J (DLBCL 83%); stage I bulky to II; complete responders to CHOP only Median 60y 0-1 = 93% II 70% E 52%, B20% NA NR No RT
  CHOP x 8 + RT 103 Median 58y 0-1 = 96% II 68% E 45% B22% NA NR IFRT 30 Gy
GELA LNH 93-1 ACVBP + CT 318 WF H-J or anaplastic according to uKC (DLBCL 81%); 15-60y; aaIPI = 0†; stages I to II Median 46y 0-1 = 100% II 32% E 46% ↑ 3% 0 = 96%† No RT
  CHOP x 3 + RT 329 Median 47y 0-1 = 100% II 32% E 52% ↑ 3% 0 = 95%† IFRT 40 Gy
GELA LNH 93-4 CHOP x 4 277 WF H-J or anaplastic according to uKC (DLBCL 80%); >60y; aaIPI = 0†; stages I to II Median 69y 0-1 = 99% II 32% Bu 8% ↑ 2% 0 = 95%† No RT
  CHOP x 4 + RT 299   Median 68y 0-1 = 99% II 34% Bu 9% ↑ 3% 0 = 95%† IFRT 40 Gy
  1. Abbreviations: ACVBP + CT: doxorubicin 75 mg/m² D1 + cyclophosphamide 1200 mg/m² D1 + vindesine 2 mg/m² D1,5 + bleomycin 10 mg D1,5 and prednisone 60 mg/m² D1-5, 3 cycles with 14 days each and then consolidative chemotherapy with methotrexate, folinic acid, etoposide, ifosfamide and cytarabine; B: “B” symptoms; Bu: bulky disease; CHOP: cyclophosphamide 750 mg/m² D1 + doxorubicin 50 mg/m² D1 + vincristine 1,4 mg/m² D1 + prednisone 60 mg/m² or 100 mg D1-5, 21 day cycles; DLBCL: diffuse large B cell lymphoma; E: extranodal disease; IFRT: involved-field radiotherapy; IPI: International Prognostic Index; LDH: lactate dehydrogenase; NA: not available; NR: not reported; uKC: updated Kiel Classification; WF: Working Formulation; † age-adjusted IPI.